Pharvaris NV (PHVS) Actualités

Pharvaris Outlines 2025 Strategic Priorities

Initiated CHAPTER-3, the pivotal Phase 3 study of deucrictibant for prophylaxis against hereditary angioedema...

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention...

Pharvaris to Participate in the Guggenheim Healthcare Innovation Conference

ZUG, Switzerland, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Pharvaris Presents Clinical and Non-Clinical Data Supporting HAE Development Program at the 2024 ACAAI Annual Scientific Meeting

ZUG, Switzerland, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at Upcoming Scientific Meetings

ZUG, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Pharvaris to Host Virtual Investor Event on October 23, 2024

ZUG, Switzerland, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Pharvaris Announces Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2024 HAEi Global Leadership Workshop

ZUG, Switzerland, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities